Table 1.
Clinical characteristics of discovery and independent validation lung cancer cohort.
| Cohort | Discovery | Validation |
|---|---|---|
| Num. of patients | 49 | 27 |
| Age in years, mean (SD) | ||
| Control | 52.7(1.0) | 45(1.85) |
| Cancer | 62.5(0.28) | 60(0.76) |
| Males, count (%) | ||
| Control | 7/13(53.8) | 6/12(50.0) |
| Cancer | 21/36(58 0.3) | 10/15(66.6) |
| Cancer type (%) | ||
| ADC | 23/36(63.8) | 9/15(60) |
| SCC | 6/36(16.7) | 3/15(20) |
| SCLC | 5/36(13.9) | 3/15(20) |
| Other | 2/36(5.6) | |
| Smoking history (%) | ||
| YES | 13/36(36.1) | 4/15(26.7) |
| NO | 23/36(63.9) | 11/15(73.3) |
| Distant metastasis (%) | ||
| YES | 18/36(50) | 3/15(20) |
| NO | 18/36(50) | 12/15(80) |
| Lymph node involvement (%) | ||
| YES | 15/36(41.7) | 4/15(26.7) |
| NO | 21/36(58.3) | 11/15(73.3) |
| Tumor stages (%) | ||
| Stage I | 10/36(27.8) | 4/15(26.7) |
| Stage II | 2/36(5.5) | 3/15(20) |
| Stage III | 6/36(16.7) | 5/15(33.3) |
| Stage IV | 18/36(50) | 3/15(20) |